Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg

ApprovedSmall molecule

WWestern University, Canada

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2027

Post-ApprovalNot yet recruiting

Dyspnea

NCT07192016

Clinical

Trials by Indication[1]

Dyspnea1 trial

129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

Not yet recruiting·WWestern University, Canada·Phase 4·NCT07192016·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Western University, Canada company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWestern University, Canada

Related News